

1. An isolated nucleic acid encoding a polypeptide comprising an alpha subunit of an eag-like potassium channel, the polypeptide:
  - (i) forming an eag-like potassium channel having the characteristic of slow activation and outward rectification; and
  - (ii) comprising an amino acid sequence having at least 80% amino acid identity to SEQ ID No:2.
2. An isolated nucleic acid encoding a polypeptide comprising an alpha subunit of an eag-like potassium channel, the polypeptide:
  - (i) forming an eag-like potassium channel having the characteristic of slow activation and outward rectification;
  - (ii) comprising an amino acid sequence having at least 95% amino acid identity to SEQ ID No:3.
3. An isolated nucleic acid encoding a polypeptide comprising an alpha subunit of an eag-like potassium channel, the polypeptide:
  - (i) forming an eag-like potassium channel having the characteristic of slow activation and outward rectification; and
  - (ii) comprising an amino acid sequence having at least 95% amino acid identity to SEQ ID No:4.
4. The isolated nucleic acid of claim 1, wherein the nucleic acid encodes a polypeptide having a molecular weight of between 100 to 150 kDa.
5. The isolated nucleic acid of claim 1, wherein the polypeptide has a molecular weight of about 123 kDa.
6. The isolated nucleic acid of claim 1, wherein the nucleic acid encodes rat elk1.
7. The isolated nucleic acid of claim 1, wherein the nucleic acid encodes human elk1.

8. The isolated nucleic acid of claim 2, wherein the nucleic acid encodes human elk2.
9. The isolated nucleic acid of claim 3, wherein the nucleic acid encodes human eag2.
10. The isolated nucleic acid sequence of claim 6, wherein the nucleic acid has a nucleotide sequence of SEQ ID No:1.
11. The isolated nucleic acid sequence of claim 7 wherein the nucleic acid is at least 80% homologous to SEQ ID NO:1.
12. The isolated nucleic acid of claim 1, wherein the nucleic acid is isolated from superior cervical ganglia, coeliac ganglia, superior mesenteric ganglia, foetal brain, adrenal or stellate ganglia by PCR using primers that selectively hybridize under stringent hybridization conditions to a pair of primers:  
5' TTY AAR RCN RYN TGG GAY TGG 3' (SEQ ID No:5) and  
3' RTA CCA DAT RCA NGC NAG CCA RTG 5' (SEQ ID No:6)  
and amplified using a pair of primers:  
5' CGG GAT CCT TGT GGA CAA AC 3' (SEQ ID NO:7) and  
3' TTC AGG AAT GAC AAC CAG GC 5' (SEQ ID NO:8).
13. The isolated nucleic acid of claim 7 encoding a polypeptide and specifically hybridizes under stringent conditions to SEQ ID No:1.
14. The isolated nucleic acid of claim 7, wherein said nucleic acid selectively hybridizes under moderately stringent hybridization conditions to a nucleotide sequence of SEQ ID No:1.
15. The isolated nucleic acid of claim 2, wherein said nucleic acid encodes the polypeptide SEQ ID NO:3.
16. The isolated nucleic acid of claim 2, wherein said nucleic acid comprises the partial sequence SEQ ID NO:13.

17. The isolated nucleic acid of claim 15, wherein the nucleic acid is isolated from superior cervical ganglia by PCR using primers that selectively hybridize under stringent hybridization conditions to a pair of primers:  
5' TTY AAR RCN RYN TGG GAY TGG 3' (SEQ ID No:5) and  
3' RTA CCA DAT RCA NGC NAG CCA RTG 5' (SEQ ID No:6)  
and amplified with a pair of primers:  
5' GTG ATA CCC ATA AAG AAT GAG 3' (SEQ ID NO:9) and  
3' CGG AAA TTC AGC ACA ATG TC 5' (SEQ ID NO:10).
18. The isolated nucleic acid of claim 3, wherein said nucleic acid partially encodes the polypeptide SEQ ID NO:4.
19. The isolated nucleic acid of claim 2, wherein said nucleic acid comprises the partial sequence SEQ ID NO:14.
20. The isolated nucleic acid of claim 18, wherein the nucleic acid is isolated from brain tissue by PCR using primers that selectively hybridize under stringent hybridization conditions to a pair of primers:  
5' TTY AAR RCN RYN TGG GAY TGG 3' (SEQ ID No:5) and  
3' RTA CCA DAT RCA NGC NAG CCA RTG 5' (SEQ ID No:6).
21. An expression vector comprising the nucleic acid of claim 1.
22. An expression vector comprising the nucleic acid of claim 2.
23. An expression vector comprising the nucleic acid of claim 3.
24. An expression vector comprising the nucleic acid of claim 4.
25. An expression vector comprising the nucleic acid of claim 5.
26. An expression vector comprising the nucleic acid of claim 6.
27. An expression vector comprising the nucleic acid of claim 7.
28. An expression vector comprising the nucleic acid of claim 8.

29. An expression vector comprising the nucleic acid of claim 9.
30. An expression vector comprising the nucleic acid of claim 15.
31. An expression vector comprising the nucleic acid of claim 18.
32. A host cell transfected with the vector of claim 21.
33. A host cell transfected with the vector of claim 22.
34. A host cell transfected with the vector of claim 23.
35. A host cell transfected with the vector of claim 24.
36. A host cell transfected with the vector of claim 25.
37. A host cell transfected with the vector of claim 26.
38. A host cell transfected with the vector of claim 27.
39. A host cell transfected with the vector of claim 28.
40. A host cell transfected with the vector of claim 29.
41. A host cell transfected with the vector of claim 30.
42. A host cell transfected with the vector of claim 31.
43. A method for identifying a compound that modulates ion flux through a slowly activated outward rectifier potassium channel selected from the group consisting of elk1, elk2, eag2, the method comprising the steps of:
  - (i) contacting the compound with a eukaryotic host cell or cell membrane in which has been expressed a polypeptide forming a potassium channel having the characteristic of slowly activated outward rectification; and
  - (ii) determining the functional effect of the compound upon the cell or cell membrane expressing the potassium channel.
44. The method of claim 43, wherein the eukaryotic host cell is *Xenopus* oocyte.

45. The method of claim 43, wherein the functional effect is determined by measuring changes in current or voltage.
46. The method of claim 43, wherein the potassium channel polypeptide is recombinant.
47. The method of claim 43, wherein the potassium channel is heteromeric.
48. The method of claim 43, wherein the potassium channel polypeptide is human *elk1*.
49. The method of claim 43, wherein the potassium channel polypeptide has an amino acid sequence of SEQ ID No:2.
50. A method of detecting the presence of *elk1* in mamalian tissue selected from the group consisting of superior cervical ganglia, coeliac ganglia, superior mesenteric ganglia, foetal brain, adrenal and stellate ganglia, the method comprising the steps of
  - (i) isolating a biological sample from the mammalian tissue,
  - (ii) contacting the biological sample with a *elk1* specific reagent that selectively associates with *elk1*; and
  - (iii) detecting the level of *elk1* specific reagent that selectively associates with the sample.
51. The method of claim 50, wherein the elk1-specific reagent is selected from the group consisting of: *elk1* specific oligonucleotide primers, and *elk1* nucleic acid probes.
52. In a computer system, a method of screening for mutations of human *eag*-like genes selected from the group consisting of *elk1*, *elk2* and *eag2*, the method comprising the steps of:
  - (i) entering into the computer system a first nucleic acid sequence encoding a slowly activated outward rectifier potassium channel polypeptide, said first nucleic acid sequence having a nucleotide sequence selected from the group consisting of of SEQ ID No:1, comprising partial SEQ ID NO:13, and partial

- SEQ ID NO: 14 and conservatively modified versions thereof;
- (ii) comparing the first nucleic acid sequence with a second nucleic acid sequence having substantial identity to the first nucleic acid sequence; and
  - (iii) identifying nucleotide differences between the first and second nucleic acid sequences.
53. The method of claim 52, wherein the second nucleic acid sequence is associated with a disease state.
54. In a computer system, a method for identifying a three-dimensional structure of EAG-like polypeptides selected from the group consisting of elk1, elk2, eag2, the method comprising the steps of:
- (i) entering into the computer system an amino acid sequence of at least 10 amino acids of a potassium channel peptide or at least 30 nucleotides of a gene encoding the polypeptide, the polypeptide having a partial amino acid sequence selected from a group consisting of a part of SEQ ID No: 2, SEQ ID NO:3, SEQ ID NO:4 and conservatively modified versions thereof; and
  - (ii) generating a three-dimensional structure of the polypeptide encoded by the amino-acid sequence.
55. The method of claim 54, wherein said amino acid sequence is a primary structure and wherein said generating step includes the steps of:
- (i) forming a secondary structure from said primary structure using energy terms determined by the primary structure; and
  - (ii) forming a tertiary structure from said secondary structure using energy terms determined by said secondary structure.
56. The method of claim 55, wherein said generating step further includes the step of forming a quaternary structure from said tertiary structure using anisotropic terms encoded by the tertiary structure.
57. The method of claim 54, further comprising the step of identifying; regions of the three-dimensional structure of the protein that bind to ligands and using the regions to identify ligands that bind to the polypeptide.